FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| wasiiiigton, | D.C. | 20549 | |
|--------------|------|-------|--|
| | | | |

| D C 20540 | - |
|-----------------|----------------|
| ton, D.C. 20549 | |
| | │ OMB APPROVAL |
| | |

| OMB Number: | 3235-0287 |
|--------------------------|-----------|
| Estimated average burden | |
| hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | Т | | | | | | | | E Palatinakin at Pan R. B. (1911) | | | | | |
|--|-----------------|--|---|------------|---|--|---|------|---|---------|--------------------|--|----------------------------------|---|--|---|--|---|--|
| Name and Address of Reporting Person* FMR LLC | | | | | | 2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS] | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | |
| (Last) 245 SUM | (Fi MER STRI | rst) EET | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 10/13/2015 Officer (give title below) X Other (specify below) See Remark 1 | | | | | | | | | | | | | |
| (Street) BOSTON | M | A | 02210 | | 4 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (Si | tate) | (Zip) | | | | | | | | | | | Form lile | а ву ма | ore man c | ле керо | rung Person | |
| | | Т | able I - N | on-D | erivat | ive S | Securities | s Ac | quired | l, Di | sposed o | f, or Be | neficiall | y Owned | | | | | |
| 1. Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Year) | | ear) i | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | | | | Beneficially Owned Follo Reported | | Form: Di (D) or In (I) (Instr. | | . Nature of ndirect seneficial ownership nstr. 4) | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction(: (Instr. 3 and | s) 1) | | | , , , , | |
| Common Stock | | 10/ | 10/13/2015 | | | | С | | 2,507,97 | 1 A | (1) | 2,507,9 | 71 | I | H H I | Beacon Bioventures Fund III Limited Partnership | | | |
| Common Stock | | | 10/ | 10/13/2015 | | | | С | | 527,009 | 527,009 A | | 3,034,980 | | I Bio I Fu Lii | | Beacon Bioventures Fund III Limited Partnership | | |
| Common Stock | | | 10/ | 13/201 | 15 | | | С | | 433,844 | I A | (1) | 3,468,8 | 24 | I | H H I | Beacon Bioventures Fund III Limited Partnership | | |
| Common Stock | | | 10/ | 13/2015 | | | | P | | 335,455 | 5 A | \$11 | 3,804,279 | | I Bi | | Beacon Bioventures Fund III Limited Partnership | | |
| | | | Table II | - Dei | rivativ | re Se | curities | Acq | uired, | Dis | posed of, | or Ben | eficially | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security | | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transaction Code (Instr. | | 5. Number of Derivative | | 6. Date Exerci Expiration Da (Month/Day/Y | | isable and | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | | 9. Number of derivative Securities Beneficially Owned Following Reported | | 10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4 | Beneficial Ownership t (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercis | able | Expiration Date | Title | Amount or Number of Shares | | (Instr. | ction(s) 4) | | | |
| Series A Convertible Preferred Stock | (1) | 10/13/2015 | | | С | | 8,652,500 | | (1) | | (1) | Common Stock | 2,507,97 | (1) | | 0 | I | Beacon Bioventures Fund III Limited Partnership | |
| Series B Convertible Preferred Stock | (1) | 10/13/2015 | | | С | | 1,818,182 | | (1) | | (1) | Common Stock | 527,009 | (1) | | 0 | | Beacon Bioventures Fund III Limited Partnership | |
| Series C Convertible Preferred Stock | (1) | 10/13/2015 | | | С | | 1,496,764 | | (1) | | (1) | Common Stock | 433,844 | (1) | | 0 | I | Beacon Bioventures Fund III Limited Partnership | |
| xplanation | of Response | es: | | | | | | | | | | | | | | | | | |

1. On October 13, 2015, in connection with the completion of the issuer's initial public offering, all shares of Convertible Preferred Stock converted into 0.289855 shares of Common Stock.

Remark 1: Edward C. Johnson 3d is a Director and the Chairman of FMR LLC. and Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Edward C. Johnson 3d and Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: Beacon Bioventures Advisors Fund III Limited Partnership is solely managed by

Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the family of Edward C. Johnson 3d.

Scott C. Goebel, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, Edward C. Johnson 3d and Abigail P.

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.